Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting

2012 ◽  
Vol 39 (11) ◽  
pp. 2189-2192 ◽  
Author(s):  
OLIVER FITZGERALD ◽  
CHRISTOPHER T. RITCHLIN ◽  
PHILIP J. MEASE
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Structural Damage ◽  
Radiographic Progression ◽  
Clinical Markers ◽  
Sample Collection ◽  
Critical Research ◽  
Specific Protocol ◽  
Radiographic Scoring Methods ◽  
Selection Of

Clinical markers of radiographic progression have been studied in patients with psoriatic arthritis (PsA), and results have clearly confirmed the progression of radiographic damage over a 2-year period. Biomarkers of radiographic progression damage (erosion and new bone formation) have also been identified as a critical research issue in these patients. At the 2011 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed development of a pivotal observational study (PsA Biodam study) to determine the validity of several soluble biomarkers in predicting structural damage in patients with PsA receiving standard therapies. Specific protocol issues discussed were the inclusion criteria, selection of candidate biomarkers, timing of sample collection, the primary radiographic outcome measure, radiographic scoring methods, possible substudies, and funding strategies.

Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

2013 ◽  
Vol 40 (8) ◽  
pp. 1407-1409 ◽  
Author(s):  
Philip J. Mease ◽  
Wolf-Henning Boehncke ◽  
Dafna D. Gladman
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Structural Damage ◽  
Research Work ◽  
Screening Tools ◽  
European Academy ◽  
The Status ◽  
Patient Groups ◽  
Peripheral Spondyloarthritis ◽  
Psoriasis Severity

The 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in June 2012 in Stockholm, Sweden, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups from around the world. In this Prologue we introduce discussions that were held among meeting attendees. Prior to the 2012 meeting, 2 GRAPPA members organized a Fellows Symposium adjacent to the European Academy of Dermatology and Venerology meeting in Verona, where they discussed comorbidities and treatments of patients with psoriasis. The 2012 GRAPPA meeting began with a trainee symposium, where 30 rheumatology fellows and dermatology residents presented their research work. Other presentations and discussions included a review of arthritis mutilans; dermatology issues including screening tools for psoriatic arthritis (PsA) and the instruments to measure psoriasis severity; cardiovascular and other comorbidities of psoriasis and PsA; development of criteria to define inflammatory arthritis, enthesitis, dactylitis, and spondylitis; distinctions between peripheral spondyloarthritis and PsA; the status of an ultrasound outcome measure for dactylitis; and updates on several GRAPPA projects, including a study of biomarkers to predict structural damage in PsA, the ongoing video project, and several education initiatives.

The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis

2015 ◽  
Vol 42 (11) ◽  
pp. 2110-2117 ◽  
Author(s):  
Mats Geijer ◽  
Ulla Lindqvist ◽  
Tomas Husmark ◽  
Gerd-Marie Alenius ◽  
Per T. Larsson ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Structural Damage ◽  
Radiographic Progression ◽  
Clinical Signs ◽  
Tender Joint Count ◽  
Radiographic Damage ◽  
Radiographic Findings ◽  
Men And Women ◽  
Radiographic Score

Objective.To describe early radiographic findings in patients from the Swedish psoriatic arthritis (SwePsA) registry, progression of destruction, correlations with clinical disease variables, and predictors of destruction.Methods.Hand and foot radiographs were available for 72 of 197 SwePsA patients followed for 5 years. Clinical data were collected according to the SwePsA protocol.Results.Disease characteristics and clinical improvement were similar in men and women. Radiographic abnormalities were more pronounced in men. Total Wassenberg radiographic score at baseline was 0 in 45% of men and 51% of women. One man and one woman had a score > 10. At 5 years, total score was 0 in 14% of men and 40% of women (p = 0.018); 17% of men and 7% of women had scores > 10. Mean total scores for men and women had increased. Baseline erythrocyte sedimentation rate was associated with baseline total radiographic score. In men, swollen joint count was positively, and in women tender joint count negatively, correlated to total radiographic score. After 5 years, only male scores, mainly hand scores, significantly correlated with 28-joint Disease Activity Score and Disease Activity Index for Psoriatic Arthritis scores, swollen joint count, and dactylitis. Achieving remission or minimal disease activity after 5 years protected against structural damage, mainly in men.Conclusion.Radiographic progression in early PsA was generally slow but substantial. Male sex appears to be a risk factor for early radiographic damage while the presence of baseline radiographic damage and dactylitis developing during followup seem to predict further destruction. Hand and foot radiograph scoring cannot be substituted with clinical signs.

The Path Forward to Biomarker Discovery in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 434-436 ◽  
Author(s):  
DAFNA D. GLADMAN ◽  
CHRISTOPHER T. RITCHLIN ◽  
OLIVER FITZGERALD
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Radiographic Progression ◽  
Biomarker Discovery ◽  
Clinical Phenotype ◽  
Inception Cohort ◽  
Psoriatic Disease ◽  
Definition Of ◽  
Biomarker Research

At the 2010 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), wide-ranging discussions were held regarding biomarker research in psoriatic disease. Consensus was reached on 2 areas of priority: (1) the study of soluble biomarkers of radiographic progression in psoriatic arthritis (PsA); and (2) the analysis of comorbidity biomarkers, specifically cardiovascular and articular, in a psoriasis inception cohort. For each of these areas, rigorous definition of the clinical phenotype of PsA will be essential. To date, 2 instruments have been identified to define the phenotype: the ClASsification of Psoriatic ARthritis criteria and various screening questionnaires. In this overview, we discuss the challenges of the clinical phenotype of PsA and review GRAPPA plans for developing a research program for biomarker discovery.

scholarly journals Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting

2021 ◽  
pp. jrheum.201667
Author(s):  
Carmel Stober ◽  
Deepak R. Jadon ◽  
April W. Armstrong ◽  
Vinod Chandran ◽  
Maarten de Wit ◽  
...  
Keyword(s):  
Risk Factors ◽  
Case Report ◽  
Psoriatic Arthritis ◽  
Treatment Response ◽  
Annual Meeting ◽  
Collaborative Research ◽  
Structural Damage ◽  
Research Network ◽  
The Usa ◽  
Axial Disease

At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)- Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a pilot investigator-initiated study protocol to test electronic case report forms (eCRFs) and proposed Standardized Operating Procedures (SOPs) to evaluate biomarkers of psoriatic arthritis (PsA) associated with axial disease. The progress on 3 studies was also presented: BioDAM PsA (Biomarkers as Predictors of structural DAMage in PsA; to validate soluble biomarkers as predictors of structural damage in PsA), PreventPsA (examining the development of PsA and risk factors among patients with psoriasis and no arthritis), and PredictORPsA (Predicting Treatment respOnse in patients with eaRly PsA; in collaboration with Pfizer using samples from the Oral Psoriatic Arthritis TriaL [OPAL], to identify biomarkers of treatment response). GRAPPA-CRN funding partnerships and applications are also underway with both the Innovative Medicines Initiative (IMI) in Europe and Accelerating Medicines Partnerships (AMP) 2.0 in the USA, and the progress of these applications and associated objectives were presented.

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group

2021 ◽  
pp. jrheum.201679
Author(s):  
Ying Ying Leung ◽  
Ana-Maria Orbai ◽  
William Tillett ◽  
Alexis Ogdie ◽  
Lihi Eder ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Physical Function ◽  
Annual Meeting ◽  
Working Group ◽  
Structural Damage ◽  
Short Form ◽  
Core Outcome Set ◽  
Health Assessment ◽  
Working Groups ◽  
Set Up

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)–Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group provided updates at the 2020 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. Working groups were set up for the 4 prioritized domains: enthesitis, fatigue, structural damage, and physical function. Two instruments for measurement of physical function were provisionally endorsed: (1) the Health Assessment Questionnaire–Disability Index and (2) the physical functioning domain in the Medical Outcomes Study 36-item Short Form survey.

Utility in Clinical Trials of Magnetic Resonance Imaging for Psoriatic Arthritis: A Report from the GRAPPA 2014 Annual Meeting

2015 ◽  
Vol 42 (6) ◽  
pp. 1044-1047 ◽  
Author(s):  
Mikkel Østergaard ◽  
Daniel Glinatsi ◽  
Susanne Juhl Pedersen ◽  
Inge Juul Sørensen
Keyword(s):  
Magnetic Resonance Imaging ◽  
Clinical Trials ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Annual Meeting ◽  
Structural Damage ◽  
Current Knowledge ◽  
Future Research ◽  
Resonance Imaging ◽  
Research Perspectives

Psoriatic arthritis (PsA) is a heterogeneous disease that involves both peripheral and axial joints and entheses. Magnetic resonance imaging (MRI) allows visualization of the inflammatory components (synovitis, tenosynovitis, enthesitis, periarticular inflammation, and bone marrow edema) as well as structural damage (bone erosion, bone proliferation) in PsA. However, MRI has not been validated as an outcome measure in PsA clinical trials to the same extent as in rheumatoid arthritis. Recently, further validation of the Outcome Measures in Rheumatology (OMERACT) PsA MRI score (PsAMRIS) was presented at the 2014 annual meeting of the Group for Research and Assessment of Psoriatic Arthritis (GRAPPA). In this review, we present the current knowledge within MRI assessment of PsA, particularly peripheral manifestations, as well as different imaging methods and scoring systems, and we discuss future research perspectives.

From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials

2013 ◽  
Vol 72 (7) ◽  
pp. 1113-1117 ◽  
Author(s):  
Robert Landewé ◽  
Vibeke Strand ◽  
Désirée van der Heijde
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trials ◽  
Psoriatic Arthritis ◽  
Structural Damage ◽  
Structural Integrity ◽  
Radiographic Progression ◽  
Methodological Framework ◽  
Drug Treatments ◽  
New Treatment ◽  
New Treatments

Usually, a clinical trial in rheumatoid arthritis and psoriatic arthritis aiming to demonstrate that a new antirheumatic drug treatment can inhibit progression of structural damage has a ‘superiority design’: The new treatment is compared to placebo or to another active treatment. Currently, many new drug treatments have shown to be able to completely suppress progression (progression rates close to zero). For largely unknown reasons, during the last 10 years, radiographic progression rates in clinical trials have gradually decreased, so that progression rates in the comparator groups are often too low to demonstrate meaningful inhibition, and thus superiority of the new treatment. We here propose an alternative framework to demonstrate that new treatments have the ability to ‘preserve structural integrity’ rather than to ‘inhibit radiographic progression’. Anno 2013, preserving structural integrity is conceptually more realistic than inhibiting radiographic progression.

Biomarkers: Project Update from the GRAPPA 2012 Annual Meeting

2013 ◽  
Vol 40 (8) ◽  
pp. 1453-1454 ◽  
Author(s):  
Oliver FitzGerald ◽  
Philip J. Mease
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Radiographic Progression ◽  
Assessment Process ◽  
Important Goal ◽  
The Past ◽  
Near Future

For members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), an important goal has been the identification of soluble biomarkers in psoriatic arthritis that might predict the development of radiographic progression. Work over the past year has resulted in approval of a draft protocol, and an announcement is forthcoming of the outcome of an assessment process for centers that applied to manage the project. GRAPPA is now ready to commence formal negotiations with potential funding partners and intends to initiate this project in the near future.

Selection of Materials and Sensors for Health Monitoring of Composite Structures

2003 ◽  
Vol 785 ◽  
Author(s):  
Seth S. Kessler ◽  
S. Mark Spearing
Keyword(s):  
Health Monitoring ◽  
Lamb Wave ◽  
Composite Structures ◽  
Structural Damage ◽  
Performance Metrics ◽  
Full Range ◽  
Transportation Systems ◽  
Health Monitoring Systems ◽  
The Relationship ◽  
Selection Of

ABSTRACTEmbedded structural health monitoring systems are envisioned to be an important component of future transportation systems. One of the key challenges in designing an SHM system is the choice of sensors, and a sensor layout, which can detect unambiguously relevant structural damage. This paper focuses on the relationship between sensors, the materials of which they are made, and their ability to detect structural damage. Sensor selection maps have been produced which plot the capabilities of the full range of available sensor types vs. the key performance metrics (power consumption, resolution, range, sensor size, coverage). This exercise resulted in the identification of piezoceramic Lamb wave transducers as the sensor of choice. Experimental results are presented for the detailed selection of piezoceramic materials to be used as Lamb wave transducers.

scholarly journals Analysis of the Gastro-Intestinal Tract of Marine Mammals: A Multidisciplinary Approach with a New Multi-Sieves Tool

Animals ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1824
Author(s):  
Giorgia Corazzola ◽  
Matteo Baini ◽  
Carla Grattarola ◽  
Cristina Panti ◽  
Federica Marcer ◽  
...  
Keyword(s):  
Cause Of Death ◽  
Marine Mammals ◽  
Intestinal Tract ◽  
Multidisciplinary Approach ◽  
Sample Collection ◽  
Important Data ◽  
New Device ◽  
Specific Protocol ◽  
Specific Analysis ◽  
Gastro Intestinal Tract

Organs and content of the gastro-intestinal tract (GIT) of marine mammals are relevant for a variety of investigations and provide data to researchers from different fields. Currently used protocols applied to the GIT for specific analysis limit the possibility to execute other investigations and important information could be lost. To ensure a proper sample collection and a multidisciplinary investigation of the GIT of marine mammals, a new multi-sieves tool and a specific protocol have been developed. This new device and approach allowed the simultaneous sampling of the GIT and its content for the main investigations concerned. The samples collected during these preliminary trials were suitable to perform all the different research procedures considered in this work. The obtained results show that with a few and easy procedural adjustments, a multidisciplinary sampling and evaluation of the GIT of marine mammals is possible. This will reduce the risk of losing important data aimed at understanding the cause of death of the animal, but also biology and ecology of marine mammals, and other important data for their conservation and habitats management.

Sign in / Sign up

Export Citation Format

Share Document